Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia

Mingming Zhang Lianxuan Liu Shan Fu Jingjing Feng Haiqiong Zheng Guoqing Wei Ruimin Hong Houli Zhao Huijun Xu Jiazhen Cui Simao Huang Xiaoyu Wu Dongrui Wang A. Chang He Huang Yong-xian Hu
Jul 2026 · Leukemia · Vol 40, pp. 1927 - 1934 · 0 citations · 35 references
Medicine

TL;DR

The initial results indicate that CD7 CAR-T cell therapy exhibits a manageable safety profile and preliminary efficacy in R/R AML patients, supporting further investigation in larger trials.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Jul 2026

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors and had manageable safety and encouraging antitumor activity in CD70-positive ccRCC.

S. Srour, J. Chahoud, A. Drakaki et al. · 0 citations
Review Open access Aug 2026

Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy

Daratumumab-based therapy may induce remission and facilitate HSCT bridging in selected patients, but findings remain hypothesis-generating because evidence is mainly from case reports and small series.

A. Al-Mashdali, Mujahid O. Abdelraof, Monia Ibrahim et al. · 0 citations
Open access Jul 2026

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.

The results of this nonrandomized clinical trial suggest that ultralow-dose META 10-19 demonstrated promising antitumor activity and a manageable safety profile in patients with R/R DLBCL.

Yong-Xian Hu, Ming-Ming Zhang, M. Gao et al. · 1 citation
Open access Jul 2026

CD4-Targeted CAR-Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia 2224687

In vivo, CAR4-DNT achieved durable leukemia clearance and prolonged survival, whereas PBS-treated mice rapidly progressed and UT-DNT recipients showed transient disease control before relapse, establishing CAR4-DNTs as a promising immunotherapy candidate for AML, supporting their further preclinical and translational d...

Shanshan Wang, Michele Nawata, Juan Arteaga et al. · 0 citations
Case report Open access Jul 2026

Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report

It is shown that persistent post-CAR-T cytopenia can serve as an early manifestation of an underlying t-MN rather than transient hematotoxicity, and Prompt and comprehensive bone marrow assessments are paramount for patients with extensive prior exposure to cytotoxic regimens to avoid catastrophic diagnostic delays.

Longmei Chen, Wan-Chao Liu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.